Co-reporter:Yunyun Yuan, Saheem A. Zaidi, David L. Stevens, Krista L. Scoggins, Philip D. Mosier, Glen E. Kellogg, William L. Dewey, Dana E. Selley, Yan Zhang
Bioorganic & Medicinal Chemistry 2015 23(8) pp: 1701-1715
Publication Date(Web):
DOI:10.1016/j.bmc.2015.02.055
Co-reporter:Yunyun Yuan, Orgil Elbegdorj, Irina O. Beletskaya, Dana E. Selley, Yan Zhang
Bioorganic & Medicinal Chemistry Letters 2013 Volume 23(Issue 18) pp:5045-5048
Publication Date(Web):15 September 2013
DOI:10.1016/j.bmcl.2013.07.043
17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan (NAQ) was previously designed following the ‘message-address’ concept and was identified as a potent and highly selective mu opioid receptor (MOR) ligand based on its pharmacological profile. We here report the preliminary structure activity relationship (SAR) studies of this novel lead compound. For the new ligands synthesized as NAQ analogues, their binding assay results showed that a longer spacer and a saturated ring system of the side chain were unfavorable for their MOR selectivity over the kappa and delta opioid receptors. In contrast, substitutions with different electronic properties at either 1′- or 4′-position of the isoquinoline ring of the side chain were generally acceptable for reasonable MOR selectivity. The majority of NAQ analogues retained low efficacy at the MOR compared to NAQ in the 35S-GTP[γS] binding assays while electron-withdrawing groups at 1′-position of the isoquinoline ring induced higher MOR stimulation than electron-donating groups did. In summary, the electronic characteristics of substituents at 1′- or 4′-position of the isoquinoline ring in NAQ seem to be critical and need to be further tuned up to achieve higher MOR selectivity and lower MOR stimulation.NAQ analogues.